The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition

Translational Oncology 2024 May [Link] Claudia Kalla, German Ott, Francesca Finotello, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Lars van der Veen, Julia Schüler, Roger Falkenstern-Ge, Joanna Kopecka, Chiara Riganti Abstract Targeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a promising therapeutic strategy. We here investigated the effect of the novel and highly…

Read More

CHST4 Gene as a Potential Predictor of Clinical Outcome in Malignant Pleural Mesothelioma

International Journal of Molecular Sciences 2024 February 14 [Link] Shoji Okado, Taketo Kato, Yuki Hanamatsu, Ryo Emoto, Yoshito Imamura, Hiroki Watanabe, Yuta Kawasumi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Tamotsu Takeuchi, Shigeyuki Matsui, Toyofumi Fengshi Chen-Yoshikawa Abstract Malignant pleural mesothelioma (MPM) develops primarily from asbestos exposures and has a poor prognosis. In this…

Read More

BAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma

Journal of Cancer Research and Clinical Oncology 2024 January 27 [Link] Tuna Han Yuce, Guntulu Ak, Selma Metintas, Emine Dundar, Oluf Dimitri Roe, Vasiliki Panou, Muzaffer Metintas Abstract Purpose: There are currently no methods to predict response to chemotherapy in pleural mesothelioma (PM). The aim of this study is to investigate the predictive and prognostic…

Read More

Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review

Pathology Oncology Research 2024 January 8 [Link] Minying Deng, Xinyi Zhang, Chen Xu, Rongkui Luo, Lingli Chen, Yuhong Zhou, Yingyong Hou Abstract Background: Malignant mesothelioma (MM) is a tumor originating from the pleura, peritoneum, or pericardial cavity. It is divided into diffuse and localized malignant mesothelioma, with four subtypes in diffuse MM: epithelioid, sarcomatoid, desmoplastic,…

Read More

Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma

Diagnostic Cytopathology 2024 January 20 [Link] Nazli Sena Şeker, Emel Tekin, Güntülü Ak, Muzaffer Metintaş, Selma Metintaş, Emine Dündar Abstract Background: Mesothelioma is a malignant neoplasm with a poor survival rate. We aimed to investigate the importance of BAP1, MTAP (IHC), and p16/CDKN2A homozygous deletion (FISH) in cytologic material obtained from pleural effusion sampling, which…

Read More

The knockdown of stathmin with si-RNA inhibits invasion of mesothelioma

Tissue and Cell 2024 January 5 [Link] Asude Aksoy, Asuman Varoglu, Ebru Etem Onalan, Ahmet Tektemur, Gokhan Artas, Mustafa Koc, Muharrem Cakmak, Siyami Aydin, Murat Kilic, Mustafa Ulas Abstract Background: To investigate the mechanism of action of stathmin1 (STMN1) in mesothelioma (MSM) and whether it has any role in its treatment. Methods: STMN1 expression was…

Read More

Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions

Archives of Pathology and Laboratory Medicine 2024 January 8 [Link] Yin P Hung, Lucian R Chirieac Abstract Context.—: Molecular testing has increasingly been utilized in the evaluation of mesothelioma. Diffuse mesothelioma comprises multiple distinct genetic subgroups. While most diffuse mesotheliomas lack oncogenic kinase mutations and instead harbor alterations involving tumor suppressors and chromatin regulators, a…

Read More

Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma

Modern Pathology 2024 January 5 [Link] Christopher A Febres-Aldana, Jason C Chang, Achim A Jungbluth, Prasad S Adusumilli, Francis M Bodd, Denise Frosina, Jerica A Geronimo, Enmily Hernandez, Helen Irawan, Michael D Offin, Natasha Rekhtman, William D Travis, Chad Vanderbilt, Marjorie G Zauderer, Yanming Zhang, Marc Ladanyi, Soo-Ryum Yang, Jennifer L Sauter Abstract 9p21 deletions…

Read More

PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma

Frontiers in Oncology 2023 December 4 [Link] Alejandro Avilés-Salas, Luis Cabrera-Miranda, Norma Hernández-Pedro, Diana Sofía Vargas-Lías, Suraj Samtani, Wendy Muñoz-Montaño, Daniel Motola-Kuba, Luis Corrales-Rodríguez, Claudio Martín, Andrés F Cardona, Cittim B Palomares-Palomares, Oscar Arrieta Abstract Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant…

Read More

Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma

Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…

Read More